News
News and events as they happenAzurity News & Events
For media inquiries email: media@azurity.com
Azurity Pharmaceuticals announces the FDA Approval of XIFYRM™ (meloxicam injection) for the Management of Moderate-to-Severe Pain in Adults
FOR IMMEDIATE RELEASE Woburn, MA — June 10, 2025 — Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved XIFYRMTM (meloxicam injection) an IV non-steroidal anti-inflammatory drug (NSAID) that offers once daily dosing.
Azurity Pharmaceuticals Completes Acquisition of Covis Pharma
MEDIA ALERT: WOBURN, MA, March 14, 2025 – Azurity Pharmaceuticals (“Azurity”) announced today the successful completion of its acquisition of Covis Group S.à r.l. (“Covis”) from existing investors. With this acquisition, Covis is now a wholly-owned subsidiary of Azurity.
AZURITY PHARMACEUTICALS, INC. ANNOUNCES AVAILABILITY OF
AZMIRO™ (testosterone cypionate) injection for intramuscular use, CIII
MEDIA ALERT: WOBURN, Mass. December 11, 2024 – Azurity Pharmaceuticals announced today the availability of Azmiro™, the first and only FDA-approved prefilled testosterone cypionate injection. Azmiro is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF
DANZITEN™ (nilotinib) tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS
MEDIA ALERT: WOBURN, Mass. Nov 14, 2024 – Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten™, the first and only nilotinib with no mealtime restrictions indicated for adult patients with newly diagnosed Philadelphia chromosome positive…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF
NYMALIZE® (NIMODIPINE) ORAL SOLUTION 30 MG/5 ML PREFILLED ENFIT® SYRINGE
MEDIA ALERT: WOBURN, Mass. September 3, 2024 – Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to serve the needs of overlooked patients, announced today that the U.S. Food and Drug Administration (FDA) has approved Nymalize® (nimodipine) oral solution in a 30 mg/5 mL prefilled ENFit® syringe…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF
MYHIBBIN™ (mycophenolate mofetil oral suspension)
MEDIA ALERT: WOBURN, Mass. May 6, 2024 – Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to serve the needs of overlooked patients, announced today that the U.S. Food and Drug Administration (FDA) has approved Myhibbin™…
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of
Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing
MEDIA ALERT: – January 24, 2024 – Woburn, Massachusetts, Azurity Pharmaceuticals, Inc. is voluntarily recalling one (1) lot (F230169A) of
Zenzedi® CII (dextroamphetamine sulfate tablets, USP) 30 mg to the consumer level. The product is being recalled due to a report…
Azurity Pharmaceuticals Acquires Slayback Pharma
MEDIA ALERT: Woburn, Mass. – September 27, 2023 – Azurity Pharmaceuticals, Inc. (“Azurity”) is pleased to announce the closing of its acquisition of Slayback Pharma LLC (“Slayback”) today from existing investors…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES U.S. AVAILABILITY OF ZONISADE™ (zonisamide oral suspension)
MEDIA ALERT: Woburn, Mass. – October 12, 2022 – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs of overlooked…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension)
Woburn, Mass. – September 2, 2022 – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative dose-forms and formulations of products to serve the needs of overlooked…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF ZONISADE™ (zonisamide oral suspension)
Woburn, Mass. – July 18, 2022 – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs of overlooked…
Azurity Pharmaceuticals Announces Richard Blackburn as New CEO
Woburn, Mass. – February 18, 2022 – Azurity Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing innovative medicines that meet the specific needs of underserved…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF FLEQSUVY™
(baclofen oral suspension)
WOBURN, MA, February 7, 2022 Azurity Pharmaceuticals, Inc., a private specialty pharmaceutical company, focused on developing innovative products to meet the unique needs of patients with underserved…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF EPRONTIA™ (topiramate) oral solution
The first and only FDA-approved ready-to-use liquid topiramate
WOBURN, MA, November 8, 2021-Azurity Pharmaceuticals, Inc. a private specialty pharmaceutical company focused on developing innovative products to meet the unique needs of patients with underserved…
Azurity Pharmaceuticals Completes Acquisition of Arbor Pharmaceuticals
WOBURN, MA & ATLANTA, GA (September 20, 2021) – Azurity Pharmaceuticals, Inc. (“Azurity”) is pleased to announce the closing of its acquisition of Arbor Pharmaceuticals, Inc. (“Arbor”), as previously announced on August 24, 2021. The acquisition creates a leading...
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of One Lot of Firvanq® (vancomycin hydrochloride for oral solution), Vancomycin 50 mg/mL Kit, Due to a Mix-Up of the Diluent Included in the Kit
FOR IMMEDIATE RELEASE – September 7, 2021 – Wilmington, MA, Azurity Pharmaceuticals, Inc. (“Azurity”) is voluntarily recalling one lot of Firvanq® (vancomycin hydrochloride for oral solution), Vancomycin 50 mg/mL Kit (“Firvanq®”) to the consumer level, as some products in the affected lot have been found to incorrectly contain a First Omeprazole (FIRST-PPI) diluent instead of the Firvanq diluent bottle.
Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals
NovaQuest Private Equity to support the continued growth of the combined innovative, patient-centric company
WOBURN, MA & ATLANTA, GA (August 24, 2021) – Azurity Pharmaceuticals, Inc. (“Azurity”) and Arbor Pharmaceuticals, Inc. (“Arbor”) today announced they have entered into a definitive agreement in which Azurity will be acquiring Arbor from
Azurity Pharmaceuticals Announces Three New Neurology Products
WOBURN, Mass. (February 8, 2021) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today the purchase of the neurology portfolio from Eton...
FDA Approves Katerzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, for Pediatric Patients 6 Years of Age and Older
WOBURN, Mass. (July 10, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today that the U.S. Food and Drug Administration (FDA) has...
CutisPharma Announces FIRVANQ™
WILMINGTON, Mass. (Apr. 2, 2018) – CutisPharma announced today the commercial launch of FIRVANQ ™ (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including...
Arbor News & Events
Arbor Supports Updated Clinical Recommendations for Restless Legs Syndrome
Arbor has long recognized the need for effective treatment options for Restless Legs Syndrome (RLS) and support for the patients who suffer from it. We are pleased to support The Updated Algorithm for The Management of RLS developed by the Scientific and Medical...
Arbor Pharmaceuticals, LLC Confirms Availability of Triptodur® (triptorelin) for Patients with Central Precocious Puberty
Company orders additional product amid reported industry shortage ATLANTA, Aug. 25, 2020 – Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, today affirmed the full availability of Triptodur® (triptorelin), a twice yearly injectable...
